Sitemap
142 articlesA complete index of every article on this site.
Biotech
- Dose reduction aimed at the staff, not the patient
- Stryker Application Points Its Surgical Imaging Business Toward Outcome Prediction
- GRAIL Wins US Coverage on Catching Foreign DNA Before a Cancer Call
- Edwards Puts the Tape Measure First: A Valve Application Built Around Aortic Root Height
- Regeneron Files on GLP-1 Payloads Tethered to a Myostatin-Antibody Chassis
- Reaching the brain through the spine, without opening the skull
- When a device reads the body upside down, it has moved
- A self-charging implant that watches its own power source
- Nine Applications, One Direction: A Concentrated Push in Pulsed-Field Ablation Catheters
- Scribe Therapeutics Files for a Nasdaq IPO, With the Deal Size Still Blank
- Four Clinical-Stage Biotechs Tapped the Equity Market in One Window — Here Are the Structures
- Medtronic's June 30 Grants Point Its Device R&D Toward Data-Paired Neuromodulation and Navigation
- Zymeworks to Buy Theravance Biopharma for $17.00 a Share Plus a Single-Asset CVR
- Sangamo Files Chapter 11, Names Lilly $50M Stalking-Horse Bidder for Its Platforms
- What "Substantial Doubt" and "Going Concern" Mean in a Biotech Filing
- How to Calculate a Biotech's Cash Runway From Its SEC Filing
- 8-K "Filed" vs. "Furnished": Item 2.02 vs. Item 8.01 Explained
- What Is a Profit-Share Opt-In (and Option-to-License) Deal Structure?
- How Tiered Royalties and Step-Downs Work in a Pharma Licensing Deal
- What Is a Contingent Value Right (CVR) in a Biotech Merger?
- What SEC Form 8-K Item 1.01 Means: "Entry Into a Material Definitive Agreement"
- How Biotech Milestone Payments ("Biobucks") Actually Work in a Licensing Deal
- Provectus Furnishes 2026 Annual-Meeting Slides in a Reg FD 8-K
- FDA Issues Two Emergency Use Authorizations for Animal Drugs Targeting New World Screwworm
- A Surgical-Robotics Leader's New Filings Point From Hardware to Procedure Data
- Genentech Is Quietly Pointing Its Cancer Bispecifics at Autoimmune Disease
- Amgen's Newest Patents Lock In the Plumbing Behind Its Bispecific Antibody Bet
- Onconetix Registers 100M Shares for Its Keystone Equity Line as a Going-Concern Warning Hangs Over the Books
- FDA Extends Its Drug-Repurposing Comment Period to July 13 — Why the Industry Should Care
- FDA Walks Back Two ANDA Withdrawals — How a Timely Objection Keeps a Generic Approval Alive
- FDA Debars an Individual From Drug Imports for Five Years — How the Debarment Power Actually Works
- FDA Denied the Brand Name 'Xyvona' — Now Sun Pharma Is Recalling the Levorphanol It Already Shipped
- Ascend Recalls 15,696 Bottles of a Blood-Pressure Combo After Olmesartan Fails Dissolution
- A Nitrosamine Impurity Pulls a Generic Duloxetine Batch — Why a 50-Bottle Recall Still Matters
- Microbot Medical's 8-K Opens 2,000+ Government Facilities to Its LIBERTY Robot
- PTC Therapeutics Files 8-K Flagging a Notes Offering With a Concurrent Repurchase
- Approval Watch: A New Label Supplement on GSK's MALARONE Shows How an Old Antimalarial Stays Alive
- Approval Watch: Lilly's EBGLYSS Clears an Efficacy Supplement — The Filing That Actually Expands a Biologic
- Approval Watch: Servier's VORANIGO (Vorasidenib) — The Priority-Reviewed Brain-Tumor Drug Keeps Its Label Moving
- Approval Watch: GSK's EXDENSUR (Depemokimab) — A Six-Month IL-5 Biologic Builds On Its First-Year Approval
- Approval Watch: Mallinckrodt's TERLIVAZ Adds a Labeling Supplement — The Long Road of a First-in-Class HRS Drug
- Approval Watch: AbbVie's RINVOQ LQ Clears a Manufacturing Supplement — Why a CMC Filing Matters to a Franchise Drug
- The 2026 Biotech-Deal Map, Read Through the Patents That Underwrite It
- CytomX's Latest Published Applications Keep Pointing at One Idea: the Conditional Antibody
- Iovance Just Locked In More of Its TIL Manufacturing Method — Here's the Coverage Map
- Cliff Watch: The CFTR Modulator Grant Behind Vertex's Most Durable Cash Flows
- Foundation Medicine's New Filings Keep Reading the Blood, Not the Tumor — Where That Points
- Bristol-Myers Squibb Just Issued an Anti-BCMA Antibody Patent — Mapping the Coverage Around It
- Deal Sheet: A BCMA/TACI Antibody Grant — and the Kind of Licensing It Invites
- Regeneron's Issued Patents Map a Manufacturing-and-Device Estate, Not Just Molecules
- Burn Report: Moderna's Cash Trajectory, From $6.8 Billion to the Defensive Line
- Natera's Latest Published Application Reinforces a Single Diagnostics Engine Across Many Tests
- Catalyst Calendar: Vertex's Pain Franchise and the Next Readouts the Filings Flag
- Smith & Nephew's Published Applications Point Toward Software-Defined Orthopaedic Surgery
- 10x Genomics' New Grant Sits Atop an Estate That Covers the Whole Single-Cell Workflow
- Term Teardown: The Ionizable-Lipid Grant That Sits Under Every mRNA Deal's Economics
- Burn Report: CRISPR Therapeutics' $423 Million in Cash and the Casgevy Economics Behind It
- Datadose's Application Wave Points to a Connected-Injection Platform Built on Data
- Element Biosciences Locks In More Sequencing-Optics Coverage in Week's Grant Batch
- Readout Wire: Vertex's Journavx — the Non-Opioid Pain Launch, Read by the Filing
- Deal Sheet: Regeneron's Eylea Ex-US Collaboration — and the Aflibercept Dependence It Reflects
- R&D Ledger: The Precision-Oncology Grant Behind the Companion-Diagnostic Economics
- Earnings Decoder: Lilly's Zepbound Volume vs. the Price It Realized
- GRAIL's New Applications Point Toward Serial Testing and Classifier Software
- GE HealthCare Leads the Week's Imaging Grants With X-Ray Detector Patents
- FDA Watch: The Gene-Edited Stem-Cell Documents Sitting Behind the Next Wave of Catalysts
- Boston Scientific's New Filings Point Toward Software-Guided Catheter Procedures
- Guardant Health's Re-Issued Blood-Test Patent Anchors a Deep Liquid-Biopsy Estate
- Reality Check: Regeneron's Eylea Dependence Meets 'Significant Competition'
- Medtronic's Valve Filing Points Toward Imaging-Guided Heart-Valve Placement
- Abbott's Issued Sensor-Inserter Patent Maps a Wearable-Glucose Hardware Estate
- Burn Report: An Anti-VEGF Eye-Disease Grant and the Capital a Single Asset Demands
- iRhythm's April Filings Point Beyond Heart Rhythm — Toward a Multi-Signal Wearable Patch
- Roche's Ventana Just Issued a Tissue-Transport Patent — Mapping the Diagnostics Hardware Around It
- Risk Factor Read: Moderna's Revenue Cliff and the Cash It Is Defending
- Boston Scientific's April Filings Point to a Smarter Console Behind Its Circulatory-Support Pumps
- Sanofi Just Issued Another Auto-Injector Patent — Mapping Its Drug-Delivery-Device Estate
- Deal Sheet: The CRISPR Therapeutics Grant That Puts a Floor Under the Pipeline's Value
- Becton Dickinson's Recent Filings Point Toward Smarter, Lower-Touch Infusion Hardware
- Tempus AI Locks In Digital-Pathology Patents as Its Diagnostics Estate Widens
- Boston Scientific's Catheter Filings Point to a Segment-Built Delivery Platform
- Singular Genomics Adds a Spatial-Omics Grant to a Sequencing-Tools Estate
- R&D Ledger: Who Actually Spends — LLY, REGN, VRTX, and MRNA, by the Filings
- Catalyst Calendar: The Tri-Agonist Application That Signals Where the Obesity Race Goes Next
- Earnings Decoder: Moderna's R&D Pullback, and the $3.1 Billion Number Behind It
- Term Teardown: The Older GLP-1 Derivative Grants That Still Anchor the Semaglutide Cash Flows
- Term Teardown: Who Controls Casgevy — the Vertex/CRISPR Economics, by the Filing
- Filing of the Week: Lilly's FY2025 10-K and the Tirzepatide Pipeline Map
- Reality Check: The Foundational CRISPR Grant That Shadows Every Gene-Editing Deal
- Deal Sheet: The Patent That Underwrites Lilly's GLP-1/GIP Franchise — and Every Deal Built on It
- The Deal Desk View: Six Years of Therapeutics Dealmaking, Read Through the Grants
- The Raise: A Harvard C-to-G Base-Editor Grant and Funding Next-Generation Editing
- Burn Report: A Novel RNA-Guided Nuclease Grant and the Editor-Discovery Burn
- FDA Watch: A Checkpoint-Bispecific Grant and the Immuno-Oncology Combination Frame
- Earnings Decoder 2025: Vertex's $2.77 Billion Quarter and the Slow Bend of Growth
- Deal Sheet: A Broad Institute Prime-Editing Grant and the Next Platform Value
- Term Teardown: A Roche FAP-Bispecific Grant and the Format-Platform Value
- Deal Sheet: An Amgen Bispecific Construct Grant and the T-Cell-Engager Race
- R&D Ledger 2025: Moderna's $4.5 Billion Research Spend in the Years After the Peak
- Readout Wire: An Astellas Claudin-Bispecific Grant and a Differentiated Target Bet
- Burn Report: A Stable-LNP Grant and the Quiet Economics of Shelf Life
- The Raise: An Ionizable-Lipid Grant and Funding the Delivery-Platform Burn
- Term Teardown: A Moderna LNP-Process Grant and the Manufacturing-Royalty Layer
- Readout Wire: An Arcturus LNP Grant and the Next-Generation mRNA Bet
- Deal Sheet: A Moderna LNP-Formulation Grant and the Delivery Platform It Protects
- Deal Sheet: A Translate Bio LNP-Process Grant and the mRNA Supply-Deal Layer
- Earnings Decoder 2024: Vertex Clears $9.8 Billion — Still Riding One Franchise
- FDA Watch 2024: Regeneron's Eylea Franchise and the Competitive Risk Its Annual Report Names
- Readout Wire: A Vertex Protease-Engineering Grant and the Pipeline-Expansion Signal
- Term Teardown: A CD33-Specific CAR Grant and the Value of a Modular Construct
- Deal Sheet: A Lonza Cell-Therapy Automation Grant and the Manufacturing-IP Layer
- FDA Watch: A Novartis Ophthalmic Grant and the Anti-VEGF Competitive Frame
- Burn Report: An Inhibitory-CAR Grant and Funding the Next-Generation Cell-Therapy Burn
- Reality Check 2023: Moderna's $19 Billion Peak — and the Cliff the Filing Quietly Implies
- R&D Ledger 2023: Inside Eli Lilly's $7.2 Billion Research Bill
- Deal Sheet: A Legend Biotech CAR Grant and Where Cell-Therapy Deal Value Sits
- Catalyst Calendar: A CD19-CAR Grant and the Cell-Therapy Readouts It Foreshadows
- The Raise: An Adverum Intravitreal-AAV Grant and Funding the Burn Behind Delivery IP
- Burn Report: An AAV-Editing Grant and the Long Burn Behind In-Vivo Delivery
- Deal Sheet: A 4D Molecular AAV-Capsid Grant and the Delivery-Platform Premium
- Deal Sheet: A Seagen LIV-1 ADC Combination Grant and the Value of Combination Claims
- Earnings Decoder 2022: Moderna's $6 Billion Quarter — and the Sustainability Question It Raises
- Term Teardown: The Anti-HER3 ADC Grant and Where the Payload Royalties Live
- Deal Sheet: The Daiichi Sankyo HER2-ADC Grant and the Licensing It Attracts
- Earnings Decoder 2022: Vertex's Trikafta Engine and the $7.5 Billion Base It Built
- Readout Wire: A PharmaMar ADC Grant and the Novel-Payload Bet
- Catalyst Calendar: An Eye-Disease Cas9 Grant and the Editing Programs It Foreshadows
- Burn Report: A FokI-Nuclease Editing Grant and How Platform IP Carries a Pre-Revenue Name
- Readout Wire: A CRISPR Therapeutics Grant for an Inherited Eye Disease
- Deal Sheet: The Broad Institute Guide-RNA Grant and Where CRISPR Platform Value Sits
- Deal Sheet: The MIT Gene-Editing Grant That Anchors a Licensing Platform
- Earnings Decoder 2021: Moderna's First Real Revenue Year — and the $5.25 Billion Cushion Behind It
- Deal Sheet 2021: The Vertex–CRISPR Therapeutics Partnership, as the 2020 Annual Report Describes It
- Term Teardown: An Agilent Modified-Guide-RNA Grant and the Tooling-Royalty Layer
- Readout Wire: A Janssen GLP-1 Fusion-Peptide Grant and the Combination Bet
- The Raise 2020: How Moderna Built a Cash War Chest Before It Had a Single Product to Sell
- Term Teardown: The Alnylam Carbohydrate-Conjugate Grant Behind a Decade of RNAi Deals
- Deal Sheet: Merck's Antibody-Peptide Conjugate Grant and the Dual-Agonism Bet
- Burn Report: A Scripps GPCR-Agonist Grant and How Early IP Carries a Thin Balance Sheet
- The Raise: A Dicerna RNAi Grant and What Platform IP Is Worth on a Balance Sheet
- Company Primer 2020: What Moderna's Annual Report Says Its mRNA Pipeline Is — On Paper
- Deal Sheet: The Sanofi Tri-Agonist Grant That Foreshadowed the GLP-1 Arms Race